T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 4, 2003, Pages 637-642

  Ausiello, C M ^a   Lande, R ^a   Stefanelli, P ^a   Fazio, C ^a   Fedele, G ^a   Palazzo, R ^a   Urbani, F ^a   Mastrantonio, P ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; INTERLEUKIN 12; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; FEMALE; INTERFERON TYPE II; LUNG; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; PERTUSSIS VACCINE; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES; VACCINATION; VACCINES, ACELLULAR;

EID: 0037767889     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.4.637-642.2003     Document Type: Article

References (47)

1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet i:955-960.
2. Ausiello, C. M., P. Sestili, C. Locardi, M. Logozzi, P. Rizza, E. Parlanti, L. Yang, A. Modica, A. Modesti, P. Musiani, and F. Belardelli. 1994. Defective response to T cell mitogens in mice injected with human immunodeficiency virus type 1-infected U937 cells. J. Gen. Virol. 75:2789-2794.
3. Ausiello, C. M., F. Urbani, A. la Sala, R. Lande, and A. Cassone. 1997. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65:2168-2174.
4. Ausiello, C. M., R. Lande, A. la Sala, F. Urbani, and A. Cassone. 1998. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J. Infect. Dis. 178:466-470.
5. Ausiello, C. M., R. Lande, F. Urbani, A. la Sala, P. Stefanelli, S. Salmaso, P. Mastrantonio, and A. Cassone. 1999. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67:4064-4071.
6. Ausiello, C. M., R. Lande, F. Urbani, B. Di Carlo, P. Stefanelli, S. Salmaso, P. Mastrantonio, and A. Cassone. 2000. Cell-mediated immunity and anti-body responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181:1989-1995.
7. Barbic, J., M. F. Leef, D. L. Burns, and R. D. Shahin. 1997. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect. Immun. 65:4904-4908.
8. Barnard, A., B. P. Mahon, J. Watkins, K. Redhead, and K. H. Mills. 1996. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 87:372-380.
9. Beckerman, K. P., H. W. Rogers, J. A. Corbett, R. D. Schreiber, M. L. McDaniel, and E. R. Unanue. 1993. Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. J. Immunol. 150:888-895.
10. Black, S. 1997. Epidemiology of pertussis. Pediatr Infect. Dis. J. 16:S85-S89.
11. Boursaux-Eude, C., S. Thiberge, G. Carletti, and N. Guiso. 1999. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 17:2651-2660.
12. Campins-Marti, M., H. K. Cheng, K. Forsyth, N. Guiso, S. Halperin, L. M. Huang, J. Mertsola, G. Oselka, J. Ward, C. H. Wirsing von Konig, and F. Zepp. 2001. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20:641-646.
13. Canthaboo, C., L. Williams, D. K. Xing, and M. J. Corbel. 2000. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines. Vaccine 19:637-643.
14. Cassone, A., C. M. Ausiello, F. Urbani, R. Lande, M. Giuliano, A. La Sala, A. Piscitelli, S. Salmaso, et al. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch. Pediatr. Adolesc. Med. 151:283-289.
15. Cherry, J. D. 1997. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 16:S90-S96.
16. Cherry, J. D., J. Gornbein, U. Heininger, and K. Stehr. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906.
17. Corbel, M. J., D. K. Xing, and J. G. Kreeftenberg. 1999. Informal consultation with manufacturers and W.H.O. ad hoc working group on mouse protection models for acellular pertussis vaccines national institute for biological standards, 12 November 1998. Biologicals 27:189-193.
18. Corbel, M. J., P. Mastrantonio, and J. G. Kreeftenberg. 2001. Ad hoc Working Group on acellular pertussis vaccines, World Health Organisation, Geneva, 27-28 July 2000. Vaccine 20:288-291.
19. Edwards, K. M., B. D. Meade, M. D. Decker, G. F. Reed, M. B. Rennels, M. C. Steinhoff, E. L. Anderson, J. A. Englund, M. E. Pichichero, and M. A. Deloria. 1995. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96:548-557.
20. Edwards, K. M. 2001. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis immunization be recommended? Clin. Infect. Dis. 32:1698-1699.
21. European Pharmacopoeia. 2002. Pertussis vaccine (acellular, component adsorbed), 4th ed. Monograph 1356. European Pharmacopoeia, Strasbourg, France.
22. Friedman, R. L., K. Nordensson, L. Wilson, E. T. Akporiaye, and D. E. Yocum. 1992. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect. Immun. 60:4578-4585.
23. Giuliano, M., P. Mastrantonio, A. Giammanco, A. Piscitelli, S. Salmaso, and S. G. Wassilak. 1998. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 132:983-988.
24. Guiso, N., C. Capiau, G. Carletti, J. Poolman, and P. Hauser. 1999. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 17:2366-2376.
25. Keitel, W. A., L. R. Muenz, M. D. Decker, J. A. Englund, C. M. Mink, D. A. Blumberg, and K. M. Edwards. 1999. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J. Infect. Dis. 180:397-403.
26. Kendrick, P. L., G. Eldering, M. K. Dixon, and J. Misner. 1947. Mouse protection tests in the study of pertussis vaccines: a comparative series using the intracerebral route of challenge. Am. J. Public Health 1947:803-810.
27. + T cells for key functions other than specific antibody production. J. Exp. Med. 191:1841-1852.
28. Mahon, B. P., M. S. Ryan, F. Griffin, and K. H. Mills. 1996. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect. Immun. 64:5295-5301.
29. Mahon, B. P., B. J. Sheahan, F. Griffin, G. Murphy, and K. H. Mills. 1997. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J. Exp. Med. 186:1843-1851.
30. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J. Infect. Dis. 181:2087-2091.
31. Manclark, C. R., B. D. Meade, and D. G. Burstyn. 1986. Serological response to Bordetella pertussis, p. 388-394. In N. R. Rose, H. Friedman, and J. L. Fahey (ed.), Manual of clinical laboratory immunology, 3rd ed. American Society for Microbiology, Washington, D.C.
32. Mastrantonio, P., M. Cerquetti, R. Cardines, R. Lande, C. M. Ausiello, and A. Cassone. 1999. Immunogenicity issues in the quality control of the new acellular pertussis vaccines. Biologicals 27:119-121.
33. Meade, B. D., A. Deforest, K. M. Edwards, T. A. Romani, F. Lynn, C. H. O'Brien, C. B. Swartz, G. F. Reed, and M. A. Deloria. 1995. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96:570-575.
34. Mills, K. H., A. Barnard, J. Watkins, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
35. Mills, K. H., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
36. Mills, K. H. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:655-677.
37. Petersen, J. W., P. H. Ibsen, K. Haslov, and I. Heron. 1992. Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis. Infect. Immun. 60:4563-4570.
38. Redhead, K., J. Watkins, A. Barnard, and K. H. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61:3190-3198.
39. Ryan, M., G. Murphy, L. Gothefors, L. Nilsson, J. Storsaeter, and K. H. Mills. 1997. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J. Infect. Dis. 175:1246-1250.
40. Ryan, M., G. Murphy, E. Ryan, L. Nilsson, F. Shackley, L. Gothefors, K. Oymar, E. Miller, J. Storsaeter, and K. H. Mills. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93:1-10.
41. Saukkonen, K., C. Cabellos, M. Burroughs, S. Prasad, and E. Tuomanen. 1991. Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization. J. Exp. Med. 173:1143-1149.
42. Senzilet, L. D., S. A. Halperin, J. S. Spika, M. Alagaratnam, A. Morris, and B. Smith. 2001. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin. Infect. Dis. 32:1691-1697.
43. Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916.
44. Tran Minh, N. N., Q. He, A. Ramalho, A. Kaufhold, M. K. Viljanen, H. Arvilommi, and J. Mertsola. 1999. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 104: e70.
45. Watanabe, M., E. Komatsu, T. Sato, and M. Nagai. 2002. Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection. FEMS Immunol. Med. Microbiol. 33:219-225.
46. Xing, D. K., R. G. Das, L. Williams, C. Canthaboo, J. Tremmil, and M. J. Corbel. 1999. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 17:565-576.
47. Zepp, F., M. Knuf, P. Habermehl, J. H. Schmitt, C. Rebsch, P. Schmidtke, R. Clemens, and M. Slaoui. 1996. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect. Immun. 64:4078-4084.